Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function

Cancer Research

Volumn 65, Issue 19, 2005, Pages 9021-9028

  Escuin, Daniel ^a,b   Kline, Erik R ^a   Giannakakou, Paraskevi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA TUBULIN; COLCHICINE; DISCODERMOLIDE; DOCETAXEL; EPOTHILONE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; MESSENGER RNA; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL NUCLEUS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DRUG PROTEIN BINDING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MICROTUBULE; MICROTUBULE ASSEMBLY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; WESTERN BLOTTING;

ALKALOIDS; ALKANES; ANTINEOPLASTIC AGENTS; CARBAMATES; CELL LINE, TUMOR; COLCHICINE; DOWN-REGULATION; EPOTHILONES; ESTRADIOL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTONES; MICROTUBULES; PYRONES; TAXOIDS; VINCRISTINE;

EID: 25444465116     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4095     Document Type: Article

References (44)

1. Kaufman B, Scharf O, Arbeit J, et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res 2004;64:3350-6.
2. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 2004;3:608-11.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
4. 2 sensing. Science 2001;292:464-8.
5. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
6. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-206.
7. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40.
8. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
9. Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 2001;11:S32-6.
10. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;13:29-37.
11. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8.
12. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
13. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
14. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
15. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508.
16. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-50.
17. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-57.
18. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
19. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
20. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000;97:2904-9.
21. Beck W, Cass C, Houghton P. Anticancer drugs from plants: Vinca alkaloids and taxanes. In: Holland J, Frei III E, Bast R, Kufe D, Morton D, Weichselbaum R, editors. Cancer medicine. 4th ed. Vol. 1. Baltimore: Williams & Wilkins; 1997. p. 1005-14.
22. Gidding CE, Kellie SJ. Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol 1999;29:267-87.
23. Guastalla JP III, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 2003;89:S16-22.
24. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;5:372-80.
25. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004;9:16-23.
26. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
27. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
28. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
29. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1α protein. J Biol Chem 2003;278:7445-52.
30. Hagen T, Taylor CT, Lam F, Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 2003)302:1975-8.
31. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
32. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98.
33. Jansen RP. mRNA localization: message on the move. Nat Rev Mol Cell Biol 2001;2:247-56.
34. Howe JG, Hershey JW. Translational initiation factor and ribosome association with the cytoskeletal framework fraction from HeLa cells. Cell 1984;37:85-93.
35. Gavrilova LP, Rutkevitch NM, Gelfand VI, et al. Immunofluorescent localization of protein synthesis components in mouse embryo fibroblasts. Cell Biol Int Rep 1987;11:745-53.
36. Heuijerjans JH, Pieper FR, Ramaekers FC, et al. Association of mRNA and eIF-2 α with the cytoskeleton in cells lacking vimentin. Exp Cell Res 1989;181:317-30.
37. r. 50,000 cap-binding protein with the cytoskeleton in baby hamster kidney cells. Proc Natl Acad Sci U S A 1982;79:2927-31.
38. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
39. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
40. Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res 1998;58:5280-4.
41. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004;3:172-5.
42. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6:33-43.
43. Tan C, de Noronha RG, Roecker AJ, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005;65:605-12.
44. Gundersen GG, Cook TA. Microtubules and signal transduction. Curr Opin Cell Biol 1999;11:81-94.